Integrin
Intergrin is a cell adhesion receptor for extracellular matrix protein binding. It is also involved in cell to cell interaction and triggers a variety of signaling pathways for cell proliferation, survival and mobility etc.
Products for Integrin
- Cat.No. Product Name Information
- GC37975 α2β1 Integrin Ligand Peptide α2β1 Integrin Ligand Peptide interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells.
- GC38873 α2β1 Integrin Ligand Peptide TFA
- GC68390 α5β1 integrin agonist-1
- GC62380 αvβ1 integrin-IN-1 αvβ1 integrin-IN-1 (Compound C8) is a potent and selective αvβ1 integrin inhibitor with an IC50 of 0.63 nM.
- GC62566 αvβ1 integrin-IN-1 TFA
- GC64932 αvβ5 integrin-IN-1 αvβ5 integrin-IN-1 is a first potent and selective αvβ5 integrin inhibitor (pIC50 = 8.2) .
-
GC69837
(R/S)-Alicaforsen
(R/S)-Alicaforsen is the racemic form of Alicaforsen, which consists of both R and S configurations. Alicaforsen is a 20-base length antisense oligonucleotide that inhibits the production of ICAM-1, an important adhesion molecule involved in the migration and transport process of white blood cells to inflammatory sites.
- GC15557 A 205804 E-selectin/ICAM-1 expression inhibitor
- GC15192 A 286982 A LFA-1/ICAM-1 interaction inhibitor
- GC65597 Abciximab Abciximab (C7E3), a chimeric mouse/human monoclonal antibody, is a glycoprotein (GP) IIb/IIIa inhibitor.
- GC34133 ATN-161 ATN-161 is a novel integrin α5β1 antagonist, which inhibits angiogenesis and growth of liver metastases in a murine model.
- GC33837 ATN-161 trifluoroacetate salt (ATN-161 TFA salt) ATN-161 trifluoroacetate salt (ATN-161 TFA salt) is a novel integrin α5β1 antagonist, which inhibits angiogenesis and growth of liver metastases in a murine model.
- GC65909 Bexotegrast Bexotegrast is a potent inhibitor of αΝβ6 integrin. Bexotegrast can be used for researching fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP) (extracted from patent WO2020210404A1, compound 5).
- GC17560 BIO 1211 An α4β1 inhibitor,selective and high affinity
- GC14208 BIO 5192 α4β1 inhibitor
- GC60077 BIO5192 hydrate BIO5192 hydrate is a selective and potent integrin α4β1 (VLA-4) inhibitor (Kd<10 pM).
- GC50078 BIRT 377 Potent negative allosteric modulator of LFA-1
- GC62872 BMS-587101 BMS-587101 is a potent and orally active antagonist of leukocyte function associated antigen-1 (LFA-1).
- GC38893 BMS-688521 BMS-688521 is a highly potent, orally active inhibitor of the LFA-1/ICAM interaction, with an IC50 of 2.5 nM in the adhesion assay and an IC50 of 60 nM in the MLR assay.
- GC50325 BOP BOP is a potent and selective dual α9β1/α4β1 integrin inhibitor with Kd values in the picomolar range.
- GC50075 BTT 3033 Selective inhibitor of integrin α2β1
- GC38128 c(phg-isoD-G-R-(NMe)k) TFA
- GC65455 c(phg-isoDGR-(NMe)k) c(phg-isoDGR-(NMe)k) is a selective and potent α5β1-integrin ligand with an IC50 of 2.9 nM.
- GC32042 Carotegrast Carotegrast is an orally available α4 integrin receptor inhibitor with anti-inflammatories activities.
- GC62143 Carotegrast methyl Carotegrast methyl (AJM300) is an orally active and selective α4 integrin antagonist.
- GC13559 Cilengitide Integrin inhibitor for αvβ3 and αvβ5
- GC61520 Cilengitide TFA Cilengitide is a potent and selective integrin inhibitor for αvβ3 and αvβ5 receptor, with IC50 values of 4 nM and 79 nM, respectively.
- GN10535 Cucurbitacin B
- GC13050 CWHM-12 An inhibitor of αV integrins
- GC17610 Cyclo (-RGDfK) An inhibitor of αvβ3 integrin
- GA21306 Cyclo(-Arg-Gly-Asp-D-Tyr-Lys) c(RGDyK) has been radioiodinated or modified with chelators for use as radiopharmaceutical.
- GC60117 Cyclo(-RGDfK) TFA Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM. Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface.
- GC34141 Cyclo(Arg-Gly-Asp-D-Phe-Val) TFA Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) is an inhibitor of integrin αvβ3, with antitumor activity.
- GC30111 Cyclo(RADfK) Cyclo(RADfK) is a selective α(v)β(3) integrin ligand that has been extensively used for research, therapy, and diagnosis of neoangiogenesis.
- GC13923 Cyclo(RGDyK) Cyclo(RGDyK) is a potent and selective αVβ3 integrin inhibitor with an IC50 of 20 nM.
- GC19128 E7820 E7820 is an angiogenesis inhibitor by suppressing integrin a2, a cell adhesion molecule expressed on endothelial cells.
- GC62182 Echistatin TFA Echistatin TFA, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation.
- GC17236 Echistatin, α1 isoform Echistatin, α1 isoform, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation.
-
GC12447
Eptifibatide Acetate
Glycoprotein (GP) IIb/IIIa inhibitor
- GC68283 Etrolizumab
- GC14804 Firategrast
- GC32562 Fradafiban (BIBU-52) Fradafiban (BIBU-52) is a nonpeptide platelet glycoprotein IIb/IIIa antagonist, which binds to the human platelet GP IIb/IIIa complex with a Kd value of 148 nM.
- GC19167 GLPG0187 An αν?integrin receptor antagonist
- GC30223 Gly-Arg-Gly-Asp-Ser Gly-Arg-Gly-Asp-Ser is a pentapeptide that forms the cell-binding domain of a glycoprotein, osteopontin.
- GC13951 GR 144053 trihydrochloride platelet fibrinogen receptor glycoprotein IIb/IIIa (GpIIb/IIIa) antagonist
- GC33323 GRGDSP GRGDSP, a synthetic linear RGD peptide, is an integrin inhibitor.
- GC34265 GRGDSP TFA GRGDSP (TFA) is an integrin inhibitor.
- GC34301 ILK-IN-2 ILK-IN-2 (OSU-T315 analog) is a ILK inhibitor.
- GC60200 ILK-IN-3 ILK-IN-3 is an integrin linked kinase inhibitor with antitumor activity.
- GC32967 Integrin Antagonists 27 Integrin Antagonists 27 is a small molecule integrin αvβ3 antagonist with binding affinity of 18 nM, as s novel anticancer agent.
- GC61613 Integrin modulator 1 Integrin modulator 1 is a potent and selective α4β1 integrin agonist, with an IC50 of 9.8 nM for RGD-binding α4β1.
- GC32787 iRGD peptide (c(CRGDKGPDC)) iRGD peptide (c(CRGDKGPDC)) is a 9-amino acid cyclic peptide, triggers tissue penetration of drugs by first binding to av integrins, then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties.
- GC38801 Irigenin Irigenin is a is a lead compound, and mediates its anti-metastatic effect by specifically and selectively blocking α9β1 and α4β1 integrins binding sites on C-C loop of Extra Domain A (EDA). Irigenin shows anti-cancer properties. It sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells.
- GC50642 LDV α4β1 (VLA-4) ligand
- GC16190 LDV FITC fluorescent ligand that binds to the α4β1 integrin (VLA-4)
- GC17263 Leukadherin 1 CD11b/CD18 activator
- GC19222 Lifitegrast Lifitegrast is an integrin lymphocyte function-associated antigen-1 (LFA-1) antagonist; inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM.
- GC36500 LXW7 LXW7, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor.
- GC32055 MK-0429 (L-000845704) MK-0429 (L-000845704) (L-000845704) is an orally active, potent, selective and nonpeptide pan-integrin antagonist with IC50 values of 1.6 nM, 2.8 nM, 0.1 nM, 0.7 nM, 0.5 nM and 12.2 nM for αvβ1, αvβ3, αvβ5, αvβ6, αvβ8 and α5β1, respectively.
- GC10048 MNS Inhibitor of Src/Syk tyrosine kinases
- GC61109 Natalizumab Natalizumab is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1).
- GC16107 Obtustatin An integrin α1β1 inhibitor
-
GC69630
Orbofiban acetate
Orbofiban acetate is an orally active platelet membrane glycoprotein IIb/IIIa antagonist that inhibits platelet aggregation.
- GC36821 OSU-T315 OSU-T315 (ILK-IN-1) is a small Integrin-linked kinase (ILK) inhibitor with an IC50 of 0.6 μM, inhibiting PI3K/AKT signaling by dephosphorylation of AKT-Ser473 and other ILK targets (GSK-3β and myosin light chain). OSU-T315 abrogates AKT activation by impeding AKT localization in lipid rafts and triggers caspase-dependent apoptosis in an ILK-independent manner. OSU-T315 causes cell death through apoptosis and autophagy.
- GC11753 P11 P11 is an antagonist of the integrin αvβ3-vitronectin interaction, with an IC50 of 1.74 pg/mL (2.414 pM).
- GC67708 PLN-1474
- GC10184 RGD (Arg-Gly-Asp) Peptides RGD (Arg-Gly-Asp) Peptides is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; binds to integrins.
- GC37524 RGD peptide (GRGDNP) TFA
- GC34402 RGD Trifluoroacetate RGD Trifluoroacetate is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; RGD Trifluoroacetate binds to integrins.
- GC16385 RGDS peptide RGDS peptide is an integrin binding sequence that inhibits integrin receptor function.
- GC37541 Risuteganib
- GC62397 RO0270608 RO0270608, the active metabolite of R411, is a dual alpha4beta1-alpha4beta7 (α4β1/α4β7) integrin antagonist.
- GC14795 RWJ 50271 LFA-1/sICAM interaction inhibitor
-
GC14143
SB273005
An αvβ3 antagonist
- GC64571 Sibrafiban Sibrafiban (RO 48-3657) is the orally active, nonpeptide, double-prodrug of Ro 44-3888 and a selective glycoprotein IIb/IIIa receptor antagonist.
- GC31993 SR121566A SR121566A is a novel non-peptide Glycoprotein IIb/IIIa (GP IIb-IIIa) antagonist, which can inhibit ADP-, arachidonic acid- and collagen-induced human platelet aggregation with IC50s of 46±7.5, 56±6 and 42±3 nM, respectively.
- GC12037 TC-I 15 α2β1 integrin inhibitor
- GC18025 TCS 2314 integrin very late antigen-4 (VLA-4; α4β1) antagonist
- GC61323 Tetrac Tetrac (Tetraiodothyroacetic acid), a derivative of L-thyroxine (T4), is a thyrointegrin receptor antagonist. Tetrac blocks the actions of T4 and 3,5,3'-triiodo-L-thyronine (T3) at the cell surface receptor for thyroid hormone on integrin αvβ3. Tetra has anti-angiogenic and anti-tumor activities.
- GC13255 Tirofiban selective platelet GPIIb/IIIa antagonist
- GC11371 Tirofiban hydrochloride monohydrate A GPIIb/IIIa antagonist
- GC37818 TR-14035 TR-14035 is a orally active dual α4β7/α4β1 integrin antagonist, with IC50 s of 7 nM and 87 nM for α4β7 and α4β1, respectively.
- GC63490 Valategrast Valategrast (R-411 free base) is a potent and orally active integrin α4β1 (VLA-4) and α4β7 dual antagonist.
- GC64212 Valategrast hydrochloride Valategrast hydrochloride (R-411) is a potent integrin α4β1 (VLA-4) and α4β7 dual antagonist.
- GC34211 Vedolizumab Vedolizumab is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
- GC37960 Zaurategrast Zaurategrast (CT7758) is a potent and oral-effective α4-integrin inhibitor.
- GC37961 Zaurategrast ethyl ester Zaurategrast ethyl ester (CDP323), the ethyl ester prodrug of CT7758, is a α4β1/α4β7 integrin antagonist used for the treatment of inflammatory and autoimmune disorders.
- GC37962 Zaurategrast ethyl ester sulfate Zaurategrast ethyl ester sulfate (CDP323 sulfate), the ethyl ester prodrug of CT7758, is a α4β1/α4β7 integrin antagonist used for the treatment of inflammatory and autoimmune disorders.